Generics trade looks simple from the outside: make quality medicine at scale and price it well. The hard part is everything else—consistent batch quality, regulatory agility, and logistics that can flex when demand spikes. This is where India has built its edge.
What “dominance” really means
42% global share is more than cost. It’s predictable release cycles, stable specs, and the ability to re-route without drama. Buyers return for reliability and reach, not just price tags.
- Standard specs across sites
- EBR coverage to speed approvals
- Supplier alternates pre-qualified
- Regional pack/artwork libraries ready to go
Where the volumes flow
Export Performance by Region
US and EU lanes dominate value; APAC, Middle East, and Africa add volume and access. EU is fast once compliant; US is exacting but consistent; APAC and Africa need agile packaging and licensing.
Access pricing without race-to-the-bottom
| Lever | Effect on price | Why it scales |
|---|---|---|
| Volume-based slots | −3–7% | Smooths utilization, lowers overheads |
| Specs harmonization | −2–5% | Less rework, faster release |
| Pack/artwork libraries | −1–3% | Avoids last-minute changes |
| Route optimization | −1–2% | Lower dwell + dispute risk |
Price advantage compounds when the work is boring—in a good way. Less variance, fewer exceptions, lower hidden costs.
Regulatory cadence (how teams stay ready)
- Planned submissions calendar by region
- Standing change-control board for artwork/licences
- Deviation analytics with weekly closure targets
- Transparent audit trails for payors and buyers
Compliance Cost Distribution
Product mix and resilience
Product Category Performance
Specialty APIs
Finished Formulations
Oncology Drugs
Biologics
Medical Devices
APIs and finished formulations complement each other: when one faces shock, the other often absorbs demand. Dual-qualification buffers single-point risks in both.
What buyers really ask (and straight answers)
| Question | Answer |
|---|---|
| How do you keep prices stable? | Specs standardization, utilization planning, and fewer exceptions keep costs predictable. |
| What if our market changes labels fast? | We maintain artwork libraries and pre-approved change windows. |
| Can you switch routes mid-campaign? | Yes. We keep alternates and buffers to protect schedules. |
Metrics that prove trust
| KPI | Top quartile | Median | Notes |
|---|---|---|---|
| First-pass QA acceptance | 98–99% | 96–97% | Quality at speed |
| Batch release lead time | 3–6 days | 7–10 days | Docs predictability |
| OTIF | 95–97% | 92–94% | Reliability at scale |
| Regulatory change-to-release | 2–4 weeks | 4–6 weeks | Prepared change control |